Fractyl Expands Management Team as Company Initiates U.S. Clinical Trial in Type 2 Diabetes
LEXINGTON, Mass.–(BUSINESS WIRE)–Fractyl Laboratories Inc. (Fractyl) today announced the hiring of Margaret Borys as Chief Commercial Officer (CCO) and Juan…
Pharmaceuticals, Biotechnology and Life Sciences
LEXINGTON, Mass.–(BUSINESS WIRE)–Fractyl Laboratories Inc. (Fractyl) today announced the hiring of Margaret Borys as Chief Commercial Officer (CCO) and Juan…
Neratinib becomes the first anti-HER2 treatment to be approved in Australia, as extended adjuvant therapy for early stage HER2-positive breast…
— If Approved, AR101 Will Be the First Medicine for This Life-Threatening Condition — BRISBANE, Calif.–(BUSINESS WIRE)–Aimmune Therapeutics, Inc. (Nasdaq:…
FLEXBUMIN 25% [Albumin (Human)], USP, 25% Solution is indicated for hypovolemia, hypoalbuminemia, (burns, Adult Respiratory Distress Syndrome (ARDS), and nephrosis),…
ATHENS, Ga–(BUSINESS WIRE)–ArunA Bio, a leader in the development of exosomes and exosome therapeutics for the treatment of neurodegenerative disorders,…
OSAKA, Japan & MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/ai?src=hash" target="_blank"gt;#ailt;/agt;–Ono Pharmaceutical Co., Ltd., a Japanese pharmaceutical research and development company, and…
CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic…
Respiratory Syncytial Virus (RSV) Human Challenge Study with EDP-938 ARGON-1 Study in Non-alcoholic Steatohepatitis (NASH) with EDP-305 WATERTOWN, Mass.–(BUSINESS WIRE)–lt;a…
First Subjects Dosed in Phase I Clinical Trial for Lead Autoimmune/Inflammatory Disease Program, ALPN-101 Completed $25 Million Private Placement Strong…
ST. HELIER, Jersey–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24NVCR&src=ctag" target="_blank"gt;$NVCRlt;/agt;–Novocure (NASDAQ:NVCR) announced today that Wilco Groenhuysen, Novocure’s Chief Financial Officer, will participate in Oppenheimer’s…